df Actinium Investors
  • April 2014 Actinium Announces Further Development of Actimab-A Manufacturing (click here)
  • April 2014 Actinium CEO Interviewed for "Small Stocks: Big Money" Airing on Fox business and Bloomberg (click here)
  • March 2014 Actinium Commneces Trading On NYSE MKT Today Under the Symbol ATNM (Click Here)
  • March 2014 Actinium To Commence Trading on NYSE MKT On March 26, 2014 (Click Here)
  • March 2014 Actinium To Present At Biocentry 21st Annual Future Leaders in Biotech Conference On March 28th (Click Here)
  • March 2014 Actinium To List Common Stock On NYSE MKT (Click Here)
  • March 2014 Actinium Announces Introduction Of The New Lot Of Lintuzumab Into The Clinic (Click here)
  • March 2014 Actinium To Present At 2nd Annual Sachs Cancer Bio Partnering and Investor Forum (Click Here)
  • March 2014 Actinium Files Annual Report On form 10-K For The Year ended December 31, 2013 (Click Here)
  • February 2014 Actinium to Present at the 24th Annual Wall Street Analyst forum Institutional Investor Conference (click here)
  • February 2014 Actinium to Host Advisory Meeting at the 2014 ASBMT and CIBMTR Conference (Click Here)
  • February 2014 New Therapy Targets Older Bone Marrow Transplant Patiens, has been published on Drug & Discovery & Development (Click Here)
  • February 2014 Physicians News Digest Article, New therapy for bone-marrow transplant gives hope to
    patients over 55 (Click Here)
  • February 2014 Actinium Presenting at BIO CEO & Investor Conference t 1:30 PM Today (Click Here)
  • January 2014 ActiniumTo Present at The 16th Annual BIO CEO & Investor Conference (Click Here)
  • January 2014 Actinium Engages Goodwin Biotechnology For Its Phase 3 Clinilcal Study (Click Here)
  • January 2014 Actinium Presenting at Biotech Showcase 2014 Today at 4:30 PM Pacific (click here)
  • January 2014 Actinium Closse Approximately $6.6 Million un Private Placement (click here)
  • January 2014 ActiniumTo Present at Biotech Showcase (click here)
  • December 2013 Actinium Announces Voting Results From Its Annual Shareholder Meeting (click here)
  • December 2013 Actinium Completes Technology Transfer for Manufacturing of Iomab (click here)
  • December 2013 Oppenheimer Healthcare Conference (click here)
  • December 2013 Actinium to Present at the 24th Annual Oppenheimer Healthcare Conference (click here)
  • December 2013 Encouraging Clinical Data From Multicenter Phase 1/2 Trial on Actinium's ACTIMAB-A Presented
    at American Society of Hematology Annual Meeting (Click Here)
  • December 2013 Actinium Presenting at the LD Micro Conference Today at 12:30PM Pacific (Click Here)
  • December 2013 Actinium Announces 2013 Annual Shareholder Meeting (Click Here)
  • December 2013 Additional Clinical Data From Multicenter Phase 1/2 trial to be presented
    at American Societey Of Hematology Annual Meeting (Click Here)
  • November 2013 Actinium To Present At The LD Micro Conference(Click Here)
  • November 2013 Actinium Announces Plans for IOMAB -B Phase 3 Pivotal Trial (Click Here)
  • November 2013 Actinium Pharmaceuticals Appoints Richard Steinhart as New Director (Click Here)
  • November 2013 Corporate Update (Click Here)
  • November 2013 Actinium To Host Corporate Update (Click Here)
  • November 2013 Actinium To Host Corporate Update And Virtual Roadshow Conference Call (Click Here)
  • October 2013 Webinar to discuss Iomab™-B at 11am EDT Today (Click Here)
  • October 2013 Actinium Pharmaceuticals Announces Upcoming Webinar to Discuss  Iomab™-B (Click Here)
  • September 2013 Actinium Pharmaceuticals Appoints Corey Sohmer as Vice President of Finance and Business Development (Click Here)
  • September 2013 Actinium Pharmaceuticals appoints Kaushik J. Dave, Ph.D.; MBA as CEO (Click Here)
  • July 2013 Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum (Click Here)
  • June 2013 Actinium Pharmaceuticals receive $3.6m from exercise of warrants (Click Here)
  • June 2013 Actinium Pharmaceuticals' Leukemia clinical data to be presented at International Symposium (Click Here)
  • May 2013 Actinium Pharmaceuticals Clinical results to be Presented at 8th International Symposium (Click here)
  • April 2013 Cactus Ventures, Inc. Changes name to Actinium (Click here)
  • February 2013 Bio CEO & Investor conference presentation (click here)
  • February 2013 Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference (download file)
  • January 2013 Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference (download file)
  • Janaury 2013 University of Pennsylvania joins Actinium Pharmaceuticals’ Multicenter Actimab-A Trial ( download file )
  • Janaury 2013 Actinium Pharmaceuticals to Present at the Biotech ShowcaseTM 2013 (download file)
  • January 2013 Actinium Pharmaceuticals, Inc. Goes Public via a Reverse Merger into Cactus Ventures, Inc. ( download file )
  • December 2012 - Actinium Pharmaceuticals, Inc. successfully completes the first closing of $5.1 million in its ongoing funding raise. ( download file)
  • December 2012 - Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting. ( download file)

  • November 2012 - Actinium Pharmaceuticals, Inc. and Philogen S.p.A. Announce Start of Pre-Clinical Development of an Alpha Therapy Based Antiangiogenesis Program. ( download file)

  • November 2012 - Actinium Sponsors Webinar on Clinical Use of Alpha Immunotherapy. ( download file)

  • October 2012 - Actinium Pharmaceuticals Announces First Place for Actimab-A Poster Presentation at the 8th Annual Hematologic Malignancies 2012 Conference. ( download file)

  • October 2012 - Actinium Pharmaceuticals Announces Presentation for Actimab-A, a Novel Targeted Immunotherapy for Acute Myeloid Leukemia at the 8th Annual Hematologic Malignancies 2012 Conference. ( download file)

  • October 2012 - Actinium Pharmaceuticals Announces Johns Hopkins University School of Medicine Joins Multicenter Phase I/II Actimab-A Trial. ( download file)

  • October 2012 - Dr. Hagop Kantarjian Joins Actinium Pharmaceuticals Clinical Advisory Board. ( download file)

  • September 2012 - Actinium Pharmaceuticals Announces New Round of Financing. ( download file)

  • September 2012 - MD Anderson Cancer Center joins Actinium Pharmaceuticals’ (API) Multicenter Actimab-A Trial. ( download file)

  • September 2012 - Gerri Henwood Joins Actinium’s Team as Chief Development Officer. ( download file)

  • September 2012 - Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Company’s Ongoing Phase I/II Trial in Acute Myeloid Leukemia. ( download file)

  • September 2012 - Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing. ( download file)

  • September 2012 - Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics. ( download file)

  • August 2012 - Actinium Pharmaceuticals Strengthens Management Team. ( download file)

  • August 2012 - Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program. ( download file)

  • August 2012 - Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actinium’s Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia. ( download file)

  • August 2012 - Actinium Featured in Xconomy Article Titled "Actinium Advances Armed Cancer Drugs, Preps for Wall Street Debut". ( download file)

  • July 2012 - Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp. ( download file)

  • July 2012 - Actinium Pharmaceuticals Succesfully Completes First Cohort in Multicenter Phase I/II Leukemia Trial of Actimab-A™. ( download file)

  • July 2012 - Actinium Pharmaceuticals Launches New Website. ( download file)

  • July 2012 - Actinium Pharmaceuticals, Inc. licenses Monoclonal Antibody from Fred Hutchinson Cancer Research Center.
    ( download file)

  • June 2012 - Actinium Pharmaceuticals Treats First Patients in Multicenter Phase 1/2 Leukemia Trial of Actimab-A™.
    ( download file)

  • December 2011 - Actinium Pharmaceuticals Announces Presentation of Interim Results from MSKCC Phase 1 AML Trial at the American Society of Hematology Meeting. ( download file)

  • October 2011 - Actinium Pharmaceuticals Raises $4.1 Million in Initial Closing of Series E Financing.
    ( download file)

  • September 2005 – Novel antibodies discovered by GSF licensed to Actinium Pharmaceuticals for the development of targeted gastric cancer treatment. ( download file )

  • March 2003 – Protein Design Labs Licenses Development Rights to SMART(™) M 195 Antibody To Actinium Pharmaceuticals. (download file )

  • January 2003 – Actinium Pharmaceuticals and Department of Energy's Pacific Northwest National Laboratory Announce Collaboration to Support Development of a Novel Cancer Treatment. ( download file)

  • November 2002 – Actinium Developing Novel Anticancers. (download file )

  • September 2002 – Actinium Pharmaceuticals announces Collaboration with Memorial Sloan Kettering Cancer Center for a Novel Targeted Cancer Immunotherapy. (download file )